Q1 Earnings Estimate for TSE:PRN Issued By Raymond James

Profound Medical Corp. (TSE:PRN) – Raymond James issued their Q1 2026 earnings per share estimates for Profound Medical in a note issued to investors on Tuesday, February 18th. Raymond James analyst M. Freeman anticipates that the company will post earnings per share of ($0.34) for the quarter. Raymond James has a “Strong-Buy” rating on the stock. The consensus estimate for Profound Medical’s current full-year earnings is ($1.90) per share. Raymond James also issued estimates for Profound Medical’s Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.27) EPS and Q4 2026 earnings at ($0.20) EPS.

Profound Medical Price Performance

Shares of PRN opened at C$9.62 on Wednesday. The company has a current ratio of 6.12, a quick ratio of 14.98 and a debt-to-equity ratio of 20.05. Profound Medical has a 1 year low of C$7.90 and a 1 year high of C$15.75. The stock has a market cap of C$202.71 million, a P/E ratio of -4.99 and a beta of 0.81. The stock’s 50-day moving average price is C$10.07 and its two-hundred day moving average price is C$10.95.

Insider Activity

In other Profound Medical news, Director Arun Menawat Dr. acquired 20,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were acquired at an average price of C$10.65 per share, for a total transaction of C$213,000.00. Also, Senior Officer Thomas Michael Tamberrino acquired 13,333 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were acquired at an average price of C$10.65 per share, for a total transaction of C$141,996.45. 8.62% of the stock is currently owned by company insiders.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.